ARVO LIVE: EU update on EyeArt with Eyenuk CEO and founder

Ophthalmology Times® talked with Kaushal Solanki, PhD, CEO and founder of Eyenuk, about EyeArt, an AI system cleared by the FDA to detect diabetic retinopathy at this year's ARVO meeting.

Video transcript

Editor’s note: Transcript lightly edited for clarity.

Kaushal Solanki, PhD:

I'm Kaushal Solanki, founder and CEO at Eyenuk, and Eyenuk is the developer of EyeArt, fully autonomous artificial intelligence system that is a first and only system to be cleared by the FDA for autonomous detection of both more than mild and vision threatening diabetic retinopathy.

I'm here to give you another exciting update of our European class to be MDR approval of diabetic retinopathy, macular degeneration, and glaucoma. And this is really exciting because we now, our users in the European Union, can detect AMD and glaucoma in addition to previously cleared diabetic retinopathy, but also, they can help [a] lot more patients who would be at risk of AMD and glaucoma as well.

Back here in the US, we continue to grow our footprint with adoption and usage of our autonomous AI technology growing month over month and adding more and more institutions and hospitals using our technology. Thank you.